Rituximab therapy after pediatric hematopoietic stem cell transplantation can cause prolonged B cell impairment and increases the risk for infections - a retrospective matched cohort study.

Tools

Preview	PDF (Publisher's version) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader 626kB
Preview	PDF (Supplementary Appendix) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader 1MB

Item Type:	Letter
Title:	Rituximab therapy after pediatric hematopoietic stem cell transplantation can cause prolonged B cell impairment and increases the risk for infections - a retrospective matched cohort study.
Creators:	Launspach, M., Temel, D., Ohlendorf, E., Zirngibl, F., Materne, B., Oevermann, L., Deubzer, H.E. ORCID: https://orcid.org/0000-0002-6115-4893, Henssen, A.G. ORCID: https://orcid.org/0000-0003-1534-778X, Künkele, A., Hundsdörfer, P., von Bernuth, H., Pruß, A., Eggert, A., von Stackelberg, A., Lang, P. and Schulte, J.H. ORCID: https://orcid.org/0000-0003-0671-1201
Keywords:	Autologous Transplantation, Cohort Studies, Hematopoietic Stem Cell Transplantation, Retrospective Studies, Risk Factors, Rituximab
Source:	Haematologica
ISSN:	0390-6078
Publisher:	Ferrata Storti Foundation
Volume:	108
Number:	1
Page Range:	267-272
Date:	January 2023
Official Publication:	https://doi.org/10.3324/haematol.2022.281134
PubMed:	View item in PubMed

Repository Staff Only: item control page

Download Statistics

Downloads

Downloads per month over past year